Sponsored Content
Intercell starts a confirmatory clinical study using the Vaccine Enhancement
Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches
Intercell starts a confirmatory clinical study using the Vaccine Enhancement / Picture: © Vindobona.org
Today Intercell AG (VSE: ICLL) announced the start of a further trial in the field of pandemic Influenza, investigating Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP) containing LT (a heat-labile toxin from E. coli) in combination with GSK's H5N1 pandemic antigen. This trial follows prior work with a non-GSK pandemic Influenza antigen carried out by Intercell under its…
or Log In
Fast News Search